tislelizumab
novartis,beigene
['oval', 'truce-02', 'bladder', 'tislelizumab']
haitao wang : 63% of people with high-risk non-muscle-invasive #bladdercancer who couldn't have complete surgical removal of their tumour who were treated w chemo (nab-paclitaxel) + immunotherapy (tislelizumab) had cystectomy-free survival at 12 months #asco22 truce-02 
she/her. CEO of @BladderCancerUK. President of @WorldBladderCan. Board member at @EauPatient. ??????????????????????????